Neurological drugs dominate the headlines, and therapeutics from snakes
Ìý
, co-founder and CEO of and 91´«Ã½ PhD alum of molecular, cellular and developmental biology, is developing appetite-suppressing molecules discovered through python biology that could offer an alternative to GLP-1 drugs with fewer gastrointestinal side effects.
Ìý
Ìý
Ìý
What could you do with a CU technology?
The Newsroom
Media Inquiries
For marketing and communication inquiries or news tips, contact Daniel Leonard,Ìýsenior marketing and communications specialist for Venture Partners at 91´«Ã½.
For media inquiries, please visit .